Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.

Abstract

Trovafloxacin is a new fluoronaphthyridone chemically and functionally related to members of the fluoroquinolone class of antimicrobial agents. The in vivo efficacy of the drug was compared with that of vancomycin by using the rabbit model of left-sided endocarditis. Rabbits infected with either a nafcillin-susceptible or -resistant test strain were treated with trovafloxacin (13.3 mg/kg of body weight every 12 h) or vancomycin (25 mg/kg of body weight every 8 h) for 4 days. In comparison with untreated controls, both antimicrobial agents effectively cleared bacteremia and significantly reduced bacterial counts in vegetations and tissues of animals infected with either test strain. No resistance to trovafloxacin emerged in test strains during therapy. We conclude that in this model trovafloxacin is as efficacious as vancomycin is and may serve as a viable alternative to vancomycin for use in humans with similar infections.

• Authors: G W Kaatz, S M Seo, J R Aeschlimann, H H Houlihan, R C Mercier, M J Rybak
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 42 Issue 2 Pg. 254-6 (Feb 1998) ISSN: 0066-4804 [Print] United States
• PMID: 9527768 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Naphthyridines
• trovafloxacin

Topics

• Animals
• Anti-Infective Agents (therapeutic use)
• Drug Resistance, Microbial
• Endocarditis, Bacterial (drug therapy)
• Fluoroquinolones
• Male
• Naphthyridines (therapeutic use)
• Outcome Assessment, Health Care
• Rabbits
• Staphylococcal Infections (drug therapy)
• Staphylococcus aureus (drug effects)